Abridge Stock
Private company — Abridge is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$176.95 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 11 August 2026
Valuation: $5.92B
Source: E, June 2025 — post-money $5.3B
Total raised: ~$830M+
Data last updated: 11 August 2026
About Abridge
Leading generative AI platform for clinical documentation: turns doctor-patient conversations into medical records.
Abridge — an AI platform that listens to a doctor-patient conversation and turns it into a ready medical record, billing codes, and prescriptions (№1 according to KLAS, 30% market share). Revenue $60M (2024) → $170M+ (2025), forecast $350–400M in 2026; operates in 250+ US healthcare systems (Kaiser Permanente, Mayo Clinic), in 2026 will process ~100 million conversations. Investors — a16z, Khosla, NVIDIA, CVS Health. IPO target — H2 2027 at a valuation of $16 billion.
- Sector: AI / Healthcare
- Headquarters: Pittsburgh, PA
- Founded: 2018
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 24 June 2025 | E | $158.48 | $5.3B |
| 17 February 2025 | D | $90.01 | $2.75B |
| 23 February 2024 | C | $33.13 | $850M |
| 26 October 2023 | B | $10.97 | $232M |
| 11 August 2022 | A1 | $8.82 | $145M |
| 6 October 2020 | A | $4.77 | $103M |
| 14 February 2019 | Seed | $2.43 | $27M |
Latest news
- A subsidiary of Inventurus sells a stake in Abridge for 10 million dollars — 6 August 2026
- Indian Inventurus sold a stake in Abridge for 10 million dollars to Alpha Square fund — 5 August 2026
- Abridge formed partnerships with Nvidia and Eli Lilly and is expanding its AI platform — 15 June 2026
- Abridge partnered with NEJM and JAMA Network — 15 April 2026
- Abridge expands from ambient scribe to active clinical intelligence — 7 April 2026
Frequently asked questions
Can I buy Abridge stock?
Not on a public exchange — Abridge is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
How much is one Abridge share?
A private company has no single official price. AXEVIL's consensus estimate is $176.95 per share as of 11 August 2026. Its most recent round implied a post-money valuation of $5.3B (June 2025).
When will Abridge IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Abridge publicly traded?
No. Abridge is a private company and its shares are not listed on any public exchange.
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.